874663--6/14/2007--ALKERMES

related topics

{product, candidate, development}

{product, liability, claim}

{financial, litigation, operation}

{stock, price, share}

{acquisition, growth, future}

{stock, price, operating}

{cost, regulation, environmental}

{regulation, change, law}

{personnel, key, retain}

{operation, international, foreign}

{regulation, government, change}

{provision, law, control}

{control, financial, internal}

{competitive, industry, competition}

{property, intellectual, protect}

{gas, price, oil}

{customer, product, revenue}

We are substantially dependent on revenues from our principal product. We are subject to risks related to the manufacture of our products. We rely to a large extent on third parties in the manufacturing of our products. The manufacture of our products is subject to government regulation. Our business involves environmental risks. We rely heavily on collaborative partners. We have very little sales and marketing experience and limited sales capabilities, which may make commercializing our products difficult. Our delivery technologies or product development efforts may not produce safe, efficacious or commercially viable products. Clinical trials for our product candidates are expensive and their outcome is uncertain. We depend on third parties in the conduct of our clinical trials for our product candidates and any failure of those parties to fulfill their obligations could adversely affect our development and commercialization plans. We may not become profitable on a sustained basis. We may require additional funds to complete our programs and such funding may not be available on commercially favorable terms and may cause dilution to our existing shareholders. The FDA or foreign regulatory agencies may not approve our product candidates. Legislative or regulatory changes could harm our business. Our revenues depend on payment and reimbursement from third-party payors, and a reduction in payment rate or reimbursement could result in decreased use or sales of our products. Failure to comply with government regulations regarding our products could harm our business. If and when approved, the commercial use of our products may cause unintended side effects or adverse reactions or incidence of misuse may appear. Patent protection for our products is important and uncertain. We may be exposed to product liability claims and recalls. We may not be successful in the development of products for our own account. If we are not able to develop new products, our business may suffer. Potential tax liabilities could adversely affect our results. Foreign currency exchange rates may affect revenue. We face competition in the biotechnology and pharmaceutical industries, and others. RISPERDAL CONSTA revenues may not be sufficient to repay RC Royalty Sub, LLC s obligations for the non-recourse RISPERDAL CONSTA secured 7% notes (the 7% Notes ). We may not be able to retain our key personnel. Future transactions may harm our business or the market price of our stock. If we issue additional common stock, shareholders may suffer dilution of their investment and a decline in stock price. Our common stock price is highly volatile. We may undertake additional strategic acquisitions in the future, and difficulties integrating such acquisitions could damage our ability to sustain profitability. Anti-takeover provisions may not benefit shareholders. We may not recoup any of our $100 million investment in Reliant. Litigation may result in financial losses or harm our reputation and may divert management resources. We face risks related to private litigation relating to our past practices with respect to equity incentives.

Full 10-K form ▸

874663--6/14/2007--ALKERMES_INC